Press Statement: Minister for Health
“I welcome today’s decision by the HSE to approve Pembrolizumab for reimbursement and I am sure this news will be a great relief to the patients affected and their families. This new drug has gone through a comprehensive assessment. As with all new drugs developed, the HSE must follow a process and I was eager that this process be concluded as a matter of urgency.
I would like to take this opportunity to acknowledge the key role that HSE Drugs Group and the National Centre for Pharmacoeconomics play in carrying out these assessments on behalf of patients.”